Clinical Trial Update: A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing fixed-dose carbidopa/levodopa/entacapone with immediate-release carbidopa/levodopa for Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Carbidopa/Levodopa (Immediate Release) (carbidopa/levodopa IR)
• Stalevo (levodopa;carbidopa;entacapone)

Snippet

Sponsor: Novartis | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED